Casi pharmaceuticals receives nasdaq deficiency notice regarding minimum market value requirement

Beijing, china / access newswire / may 7, 2025 / casi pharmaceuticals, inc. (nasdaq:casi), ("casi" or the "company"), a cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has received a notice (the "notice") from the nasdaq stock market llc ("nasdaq") dated may 5, 2025 stating that the company is not in compliance with the requirement to maintain a minimum market value of listed securities ("mvls") of $35 million as set forth under nasdaq listing rule for continued listing on the nasdaq capital market. nasdaq listing rule 5550(b)(2) requires companies to maintain a minimum mvls of $35 million (the "mvls requirement"), and nasdaq listing rule 5810(c)(3)(c) specifies that a deficiency occurs if the mvls falls below this threshold for 30 consecutive business days.
CASI Ratings Summary
CASI Quant Ranking